Rebecca C. Obeng, Ph.D.

2011 University of Virginia, Charlottesville, VA 
Immunology, Oncology, Cell Biology
"Rebecca Obeng"


Sign in to add mentor
Victor H. Engelhard grad student 2011 UVA
 (Tumor-associated HLA-A*0201-restricted phosphopeptides as candidates for cancer immunotherapy.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Eberhardt CS, Kissick HT, Patel MR, et al. (2021) Functional HPV-specific PD-1 stem-like CD8 T cells in head and neck cancer. Nature
Pinczewski J, Obeng RC, Slingluff CL, et al. (2021) Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2. Pathology, Research and Practice. 224: 153527
Obeng RC, Ambakhutwala AL. (2021) Generation of Phosphopeptide-Specific T Cell Lines as Tools for Melanoma Immunotherapy. Methods in Molecular Biology (Clifton, N.J.). 2265: 655-670
Engelhard VH, Obeng RC, Cummings KL, et al. (2020) MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. Journal For Immunotherapy of Cancer. 8
Zarling AL, Obeng RC, Desch AN, et al. (2014) MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer. Cancer Research. 74: 6784-95
Zarling AL, Obeng RC, Cummings KL, et al. (2012) Abstract 1584: MHC-restricted phosphopeptides as broad-based immunotherapeutic targets for cancer Cancer Research. 72: 1584-1584
Obeng RC, Poole ICL, Hunt DF, et al. (2010) Abstract B14: A phosphorylated β-catenin peptide that is presented by HLA-A2 MHC molecules generates strong phosphospecific T cell responses against melanoma Clinical Cancer Research. 16
See more...